Aug 29, 2024 / 08:00AM GMT
Erik Digman Wiklund - Circio Holding ASA - Chief Executive Officer
Welcome to Circio and our first half year report for 2024. My name is Erik Digman Wiklund, I'm the CEO. And together with me today, I also have CFO, Lubor Gaal. During this webcast, -- we just let everyone in, some latecomers.
During this webcast, we will be presenting you an update on our circVec, circular RNA technology development. At the beginning, we will talk about our new gene therapy programs. And at the end, Lubor Gaal will run us through the financials. So with that, I move into the presentation.
Starting with our circVec development. As a bit of background, circular RNA is a very novel area in therapeutic development. It's really only emerged in the past three years. And in these three years, we've seen a very substantial activity in company formation as well as deals highlighted by this slide here.
So far, two big pharmas, Merck and Pfizer have made moves into the circular RNA field. I think over time, we expect more to start entering this space because of the intrinsic advantages of circular RNA.
Half Year 2024 Circio Holding ASA Earnings Call Transcript
Aug 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers